For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Nissan Chemical Sues Three More Generic Makers over Livalo Patent Infringement
February 18, 2014
- Daiichi Sankyo, UMN Pharma Sign Collaborative Research Deal for Norovirus Vaccine
February 18, 2014
- Blopress AGs Approved, Yet Blurry Prospect for Their June Listing
February 17, 2014
- Kissei, Alteogen Agree on Business Collaboration for Biosimilar Development
February 17, 2014
- LEO Pharma’s New Japan Head Takes Office
February 17, 2014
- Once-Monthly Injectable Abilify Maintena Approved in Canada: Otsuka, Lundbeck
February 17, 2014
- New Suspicion Hints Close Link between Novartis, SIGN Initiator Group
February 17, 2014
- Nichi-Iko on Tap to Enter US Market, Remicade Biosimilar Debut Eyed around 2018
February 14, 2014
- Qol to Introduce Bidding System for Drug Purchasing Aimed at Avoiding Reduction in Basic Dispensing Fees Received
February 14, 2014
- Ex-Bellsystem24 Exec Deguchi to Spearhead AbbVie Japan
February 13, 2014
- Kyowa Kirin Temporarily Drops Untreated ATL Indication for Poteligeo
February 13, 2014
- Kaken Licenses Container Technology for Efinaconazole to Valeant
February 13, 2014
- AnGes Sales Up 10.5% but Logs 1,409 Million Yen Net Loss in 2013
February 12, 2014
- Ethical Drug Sales Up 4.7% in December: Crecon Report
February 12, 2014
- Asahi Kasei Pharma Completes 2nd Manufacturing Facility at Nagoya Pharmaceuticals Plant
February 12, 2014
- Novartis Appoints Former Tokyo High Court Judge to Head Independent Commission to Investigate Scandal Over SIGN Study
February 10, 2014
- Transdermal Parkinson’s Disease Treatment Ropinirole Shows Significant Difference in PII Study: Hisamitsu
February 10, 2014
- Mitsubishi Chemical to Set Up New Healthcare Firm
February 7, 2014
- MTPC Appoints Development Division Manager as New Representative Director
February 7, 2014
- Takeda CFO Says Midterm Strategy Not Affected by Halt of TAK-875 Trials
February 7, 2014
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…